Unlocking the potential of membrane proteins.
Abilita Therapeutics is a discovery and development company drugging the most challenging targets in medicine — multi-span membrane proteins long considered intractable — through directed evolution and AI-guided design.
The most validated drug targets in medicine remain largely untapped.
Multi-span membrane proteins represent 60% of approved drug targets — yet only 15% of the more than 2,000 in the human proteome have ever been successfully drugged. Abilita's EMP™ platform turns the rest into tractable substrates for small-molecule, antibody, and ADC discovery.
- 16MMP targets stabilised
- 5Internal discovery programs
- 2Cryo-EM structures determined
- 60%of approved drugs target MMPs
Stabilising intractable targets through directed evolution.
At the core of Abilita is EMP™ — Enabled Membrane Protein technology — a directed-evolution approach that stabilises intractable receptors in defined active or inactive states. The result is a protein you can actually screen against, structure, and design drugs for.
+ ion channels, transporters
inactive states
Lab in the loop. Human in the loop.
AI/ML is embedded across the EMP™ discovery engine. Proprietary datasets generated by the platform feed task-specific models — including our internal StabLyzeGraph tool, co-developed with the Cosconati Lab — that guide design, ranking, and experimental planning. Lab in the loop, human in the loop.
Six programs. First-in-class targets.
Six programs spanning oncology and metabolic disease. Internal small molecules and antibodies on first-in-class targets; partnered campaigns with global pharma. Every program is built on an EMP-stabilised receptor.
- GPR75ObesitySmall moleculeIn vitro Lead — 2H 2026
- GPR87NSCLC, Head & NeckmAb (ADCC or ADC)In vivo POC — 1H 2027
- GPR81PDAC, TNBCmAbIn vivo POC — 1H 2027
- MultipleMultiplemAb / ADCIn vivo POC
- CCR8CRC, SCLC, othersmAbPartnering activities ongoing
- Undisclosed w/ OrionUndisclosedmAbPartnered at discovery stage
Collaborations with Lilly, Amgen, BMS, GSK, Regeneron, and Orion validate EMP™ across antibody and small-molecule discovery against historically undruggable targets.
Drugging targets previously considered undruggable.
Partnering, investment, and research inquiries welcome.
info@abilitatx.com